---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-034123"
form_type: "8-K"
ticker: "ANGO"
cik: "0001275187"
company_name: "ANGIODYNAMICS INC"
filed_at: "2023-07-12T23:59:59+00:00"
generated_at: "2026-06-13T09:19:34.920595+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AngioDynamics Q4 net sales up 4.7% to $91.1M; GAAP loss $0.54/share

## Summary
- Med Tech segment grew 17.2% to $26.5M, driven by Auryon +22%, NanoKnife +28%, AlphaVac +87%.
- GAAP net loss $21.5M ($0.54/share) includes $14.5M goodwill impairment from divestiture of Dialysis/BioSentry to Merit Medical for $100M cash.
- FY2024 guidance: net sales $328-333M; gross margin 50-52%; adjusted loss per share $0.28-$0.34.
- Pro forma revenue for FY23 (ex-divested businesses) was $306.3M; adjusted loss $0.43/share.
- Subsequent to quarter end, used divestiture proceeds to extinguish $50M debt; cash $44.6M at May 31.

## SEC filing metadata
- accession: 0001140361-23-034123
- form_type: 8-K
- ticker: ANGO
- cik: 0001275187
- company_name: ANGIODYNAMICS INC
- filed_at: 2023-07-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1275187/000114036123034123/0001140361-23-034123-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1275187/000114036123034123/brhc20055777_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-034123
- JSON: https://secwatch.observer/filing/0001140361-23-034123.json
- Plain text: https://secwatch.observer/filing/0001140361-23-034123.txt

## Key facts
- Earnings Releases
  ANGIODYNAMICS INC reported fiscal fourth quarter ended May 31, 2023 results: revenue $91.1 million, net income net loss of $21.5 million, EPS GAAP loss per share of $0.54. Guidance initiated.
  - Period: fiscal fourth quarter ended May 31, 2023
  - Revenue: $91.1 million
  - Net income: net loss of $21.5 million
  - EPS: GAAP loss per share of $0.54
  - Guidance: initiated
  - Result: reported results
  source text: Fiscal Year 2023 Fourth Quarter Highlights • Net sales of $91.1 million increased 4.7% compared to the prior-year quarter o Med Tech net sales of $26.5 million increased 17.2% o Med Device net sales of $64.6 million increased 0.3% • Gross margin of 50.9% declined 250 basis points year over year • GAAP loss per share of $0.54, inclusive of a goodwill impairment of $14.5 million, or $0.37 per share, in connection with the transaction announced on June 8, 2023 • Adjusted earnings per share of $0.02
  evidence_url: https://www.sec.gov/Archives/edgar/data/1275187/000114036123034123/0001140361-23-034123-index.htm
- Earnings Releases
  ANGIODYNAMICS INC reported fiscal year ended May 31, 2023 results: revenue $338.8 million, EPS GAAP loss per share of $1.33. Guidance initiated.
  - Period: fiscal year ended May 31, 2023
  - Revenue: $338.8 million
  - EPS: GAAP loss per share of $1.33
  - Guidance: initiated
  - Result: reported results
  source text: Full-Year 2023 Highlights • Net sales of $338.8 million increased 7.1% year over year • Gross margin declined 100 basis points year over year to 51.4% • GAAP loss per share of $1.33 , inclusive of a goodwill impairment of $14.5 million, or $0.37 per share, in connection with the transaction announced on June 8, 2023 • Adjusted loss per share of $0.06
  evidence_url: https://www.sec.gov/Archives/edgar/data/1275187/000114036123034123/0001140361-23-034123-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.